High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus

Genes and Immunity

Volumn 8, Issue 6, 2007, Pages 492-502

  Niewold, T B ^a   Hua, J ^a   Lehman, T J A ^a   Harley, J B ^b   Crow, M K ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; DOUBLE STRANDED DNA ANTIBODY; RNA ANTIBODY;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ETHNICITY; FEMALE; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC TRAIT; HERITABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RELATIVE; RISK ASSESSMENT; RISK FACTOR; SIBLING; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; CASE-CONTROL STUDIES; CELL LINE; FEMALE; HUMANS; INTERFERON-ALPHA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; RISK FACTORS; RNA-BINDING PROTEINS;

EID: 34548438559     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364408     Document Type: Article

References (32)

1. Blanco P, Palucka AK, Gill M, Pascual V, Banchereau J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 2001; 294: 1540-1543.
2. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987; 70: 562-569.
3. Kirou KA, Lee C, George S, Louca K, Peterson MG, Crow MK. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum 2005; 52: 1491-1503.
4. Ronnblom LE, Alm GV, Oberg KE. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumour. J Intern Med 1990; 227: 207-210.
5. Niewold TB, Swedler WI. Systemic lupus erythematosus arising during interferon-α therapy for cryoglobulinemic vasculitis associated with hepatitis C. Clin Rheumatol 2005; 24: 178-181.
6. Bennett L, Palucka. AK, Arce E, Cantrell V, Borvak J, Banchereau J et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003; 197: 711-723.
7. Kirou KA, Lee C, George S, Louca K, Papagiannis IG, Peterson MG et al. Coordinate overexpression of interferon-α-induced genes in systemic lupus erythematosus. Arthritis Rheum 2004; 50: 3958-3967.
8. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003; 100: 2610-2615.
9. Tsao BP, Grossman JM, Riemekasten G, Strong N, Kalsi J, Wallace DJ et al. Familiality and co-occurrence of clinical features of systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2678-2685.
10. Scofield RH, Bruner GR, Harley JB, Namjou B. Autoimmune thyroid disease is associated with a diagnosis of secondary Sjogren's syndrome in familial systemic lupus. Ann Rheum Dis 2007; 66: 410-413.
11. Ioannou Y, Isenberg DA. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum 2000; 43: 1431-1442.
12. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005, 76: 528-537.
13. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW et al. A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 2006; 38: 550-555.
14. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum 2006; 54: 1906-1916.
15. Jabs WJ, Hennig C, Zawatzky R, Kirchner H. Failure to detect antiviral activity in serum and plasma of healthy individuals displaying high activity in ELISA for IFN-α and IFN-beta. J Interferon Cytokine Res 1999; 19: 463-469.
16. Risch N. Linkage strategies for genetically complex traits. I. Multilocus models. Am J Hum Genet 1990; 46: 222-228.
17. Rybicki BA, Elston RC. The relationship between the sibling recurrence-risk ratio and genotype relative risk. Am J Hum Genet 2000, 66: 593-604.
18. Lovgren T, Eloranta ML, Bave U, Alm GV, Ronnblom L. Induction of interferon-α production in plasmacytoid dendritic cells by immune complexes containing nucleic acid released by necrotic or late apoptotic cells and hipus IgG. Arthritis Rheum 2004, 50: 1861-1872.
19. Ramos PS, Kelly JA, Gray-McGuire C, Bruner GR, Leiran AN, Meyer CM et al. Familial aggregation and linkage analysis of autoantibody traits in pedigrees multiplex for systemic lupus erythematosus. Genes Immun 2006; 7: 417-432.
20. Bengtsson AA, Sturfelt G, Truedsson L, Blomberg J, Alm G, Vallin H et al. Activation of type I interferon system in systemic lupus; erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 2000; 9: 664-671.
21. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349: 1526-1533.
22. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, Eloranta ML et al. Activation of the type I interferon system in primary Sjogren's syndrome: A possible etiopathogenic mechanism. Arthritis Rheum 2005; 52: 1185-1195.
23. Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom. L. Induction of interferon-α by immune complexes or liposomes; containing systemic lupus erythematosus autoantigen- and Sjogrens syndrome autoantigen-associated RNA. Arthritis Rheum 2006; 54 1917-1927.
24. Consortium. Initial sequence of the chimpanzee genome and comparison with the human genome. Nature 2005; 437: 69-87.
25. Wang ET, Kodama G, Baldi P, Moyzis RK. Global landscape of recent inferred Darwinian selection for Homo sapiens. Proc Natl Acad Sci USA 2006; 103: 135-140.
26. Taniguchi T, Takaoka A. A weak signal for strong responses: interferon-α/beta revisited. Nat Rev Mol Cell Biol 2001; 2: 378-386.
27. Whitney AR, Diehn M, Popper SJ, Alizadeh AA, Boldrick JC, Relman DA et al. Individuality and variation in gene expression patterns in human blood. Proc Natl Acad Sci USA 2003; 100: 1896-1901.
28. Graham RR, Kyogoku C, Sigurdsson S, Vlasova IA, Davies LR, Baechler EC et al. Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc Natl Acad Sci USA 2007; 104; 6758-6763.
29. Kozyrev SV, Lewen S, Reddy PM, Pons-Estel B, Witte T, Junker P et al. Structural insertion/deletion variation in IRF5 is associated with a risk haplotype and defines the precise IRF5 isoforms expressed in systemic lupus erythematosus. Arthritis Rheum 2007; 56: 1234-1241.
30. von Wussow P, Jakschies D, Hartung K, Deicher H. Presence of interferon and anti-interferon in patients with systemic lupus erythematosus. Rheumatol Int 1988; 8: 225-230.
31. Griffiths AJF, Gelbart WM, Miller JH, Lewontin RC. Modern Genetic Analysis, 7th edn. WH Freeman Publishers: New York, NY, 1999.
32. Olson JM, Witte JS, Elston RC. Association within twin pairs for a dichotomous trait. Genet Epidemiol 1996; 13: 489-499.